| Daridorexant for treating long-term insomnia | TA922 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Virtual ward platform technologies for acute respiratory infections: early value assessment | HTE13 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Bimekizumab for treating axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Urinary incontinence in neurological disease: assessment and management | CG148 | | |
| Suspected neurological conditions: recognition and referral | NG127 | | |
| Hearing loss in adults: assessment and management | NG98 | | |
| Intrapartum care | NG235 | | |
| COVID-19 rapid guideline: haematopoietic stem cell transplantation | NG164 | | |
| Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment | HTE11 | | |
| KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment | HTE10 | | |
| Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | IPG772 | | |
| Birch bark extract for treating epidermolysis bullosa | HST28 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Chronic obstructive pulmonary disease in adults | QS10 | | |
| Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG770 | | |
| Cryotherapy for chronic rhinitis | IPG771 | | |
| Cirrhosis in over 16s: assessment and management | NG50 | | |
| Spinal metastases and metastatic spinal cord compression | NG234 | | |
| Spinal metastases and metastatic spinal cord compression | QS56 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |